Next-generation sequencing (NGS) technologies are high-throughput methods for DNA
sequencing and have become a widely adopted tool in cancer research. The sheer amount …

The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …

Immunotherapies targeting the programmed cell death 1 (PD-1) and cytotoxic T lymphocyte
antigen 4 (CTLA-4) checkpoint receptors have revolutionised the treatment of metastatic …

Introduction The favorable outcomes with immunotherapy for mesothelioma were somewhat
unexpected because this tumor has a low tumor mutation burden which has been …

Abstract Background In the United States, cancer disproportionately impacts Black and
African American individuals. Identifying genetic factors underlying cancer disparities has …

Introduction RBM10 is one of the frequently mutated genes in lung adenocarcinoma (LUAD).
Previous studies have confirmed that RBM10 could suppress the disease progression and …

Simple Summary Solid tumors account for~ 60% of pediatric, as well as adolescent and
young adult (AYA), cancers, and outcomes for patients with these progressive diseases …

Background Only a fraction of lung adenocarcinoma (LUAD) patients are eligible for
immunotherapy. The identification of biomarkers for immunotherapy is crucial to improve …

Accurately identifying somatic mutations is essential for precision oncology and crucial for
calculating tumor-mutational burden (TMB), an important predictor of response to …

Background Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for
patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab …